journal article·2018-04Open access

Dual‐Drug Delivery Using Dextran‐Functionalized Nanoparticles Targeting Cardiac Fibroblasts for Cellular Reprogramming

Mónica P. A. Ferreira, Virpi Talman, Giulia Torrieri, Dongfei Liu, Gonçalo Marques, Karina Moslova, Zehua Liu, João F. Pinto, Jouni Hirvonen, Heikki Ruskoaho, Hélder A. Santos

Advanced Functional Materials· Volume 28· Issue 15

Abstract

Abstract The inability of the heart to recover from an ischemic insult leads to the formation of fibrotic scar tissue and heart failure. From the therapeutic strategies under investigation, cardiac regeneration holds the promise of restoring the full functionality of a damaged heart. Taking into consideration the presence of vast numbers of fibroblasts and myofibroblasts in the injured heart, direct fibroblast reprogramming into cardiomyocytes using small drug molecules is an attractive therapeutic option to replenish the lost cardiomyocytes. Here, a spermine‐acetalated dextran‐based functional nanoparticle is developed for pH‐triggered drug delivery of two poorly water soluble small molecules, CHIR99021 and SB431542, both capable of increasing the efficiency of direct reprogramming of fibroblast into cardiomyocytes. Upon functionalization with polyethylene glycol and atrial natriuretic peptide, the biocompatibility of the nanosystem is improved, and the cellular interactions with the cardiac nonmyocytes are specifically augmented. The dual delivery of the compounds is verified in vitro, and the compounds exerted concomitantly anticipate biological effects by stabilizing β‐catenin (CHIR99021) and by preventing translocation of Smad3 to the nucleus of (myo)fibroblasts (SB431542). These observations highlight the potential of this nanoparticle‐based system toward improved drug delivery and efficient direct reprogramming of fibroblasts into cardiomyocyte‐like cells, and thus, potential cardiac regeneration therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki FI‐00014 Helsinki Finland

Drug Research Program Division of Pharmacology and Pharmacotherapy Faculty of Pharmacy University of Helsinki FI‐00014 Helsinki Finland

Helsinki Institute of Life Science, HiLIFE University of Helsinki FI‐00014 Helsinki Finland

Faculty of Pharmacy University of Lisbon 1649‐003 Lisbon Portugal

Department of Chemistry University of Helsinki FI‐00014 Helsinki Finland

Funding

Academy of Finland · Helsingin Yliopisto · European Research Council

References (85)

Show source-provided references
1. World Health Organization Cardiovascular diseases (CVDs) http://www.who.int/mediacentre/factsheets/fs317/en/(accessed: June 2017).
2. 10.1126/science.120070810.1126/science.1200708 ↗
3. 10.1038/nrm361910.1038/nrm3619 ↗
4. 10.1016/S0008-6363(99)00212-610.1016/S0008-6363(99)00212-6 ↗
5. 10.1161/RES.0b013e318258252310.1161/RES.0b013e3182582523 ↗
6. 10.1007/s00441-016-2431-910.1007/s00441-016-2431-9 ↗
7. 10.1038/sj.bjp.070731510.1038/sj.bjp.0707315 ↗
8. 10.1038/gt.2016.4310.1038/gt.2016.43 ↗
9. 10.1161/JAHA.113.00011910.1161/JAHA.113.000119 ↗
10. 10.1016/j.ncrna.2017.03.00110.1016/j.ncrna.2017.03.001 ↗
11. 10.1038/nature0680010.1038/nature06800 ↗
12. 10.3892/ijmm.2016.260710.3892/ijmm.2016.2607 ↗
13. 10.5966/sctm.2012-003010.5966/sctm.2012-0030 ↗
14. 10.1016/j.jacbts.2016.11.00810.1016/j.jacbts.2016.11.008 ↗
15. 10.1007/s12265-010-9207-510.1007/s12265-010-9207-5 ↗
16. 10.1016/j.cell.2006.07.02410.1016/j.cell.2006.07.024 ↗
17. 10.1038/nature1113910.1038/nature11139 ↗
18. 10.1016/S0140-6736(16)30137-410.1016/S0140-6736(16)30137-4 ↗
19. 10.1016/S0140-6736(11)61590-010.1016/S0140-6736(11)61590-0 ↗
20. 10.1016/j.jacc.2013.08.72410.1016/j.jacc.2013.08.724 ↗
21. 10.1016/j.addr.2015.06.01310.1016/j.addr.2015.06.013 ↗
22. 10.5966/sctm.2015-011410.5966/sctm.2015-0114 ↗
23. 10.1038/nprot.2012.15010.1038/nprot.2012.150 ↗
24. 10.1038/srep2463710.1038/srep24637 ↗
25. 10.1038/ncomms924310.1038/ncomms9243 ↗
26. 10.1124/mol.62.1.6510.1124/mol.62.1.65 ↗
27. 10.1371/journal.pone.008967810.1371/journal.pone.0089678 ↗
28. 10.1371/journal.pone.001113410.1371/journal.pone.0011134 ↗
29. 10.1186/s13619-015-0017-810.1186/s13619-015-0017-8 ↗
30. 10.1016/j.celrep.2014.01.03810.1016/j.celrep.2014.01.038 ↗
31. 10.2174/138945011599914103014392310.2174/1389450115999141030143923 ↗
32. 10.2174/092986652166614080711424010.2174/0929866521666140807114240 ↗
33. 10.2217/nnm.16.610.2217/nnm.16.6 ↗
34. 10.1016/j.jconrel.2010.07.09710.1016/j.jconrel.2010.07.097 ↗
35. 10.1016/j.jconrel.2013.04.02210.1016/j.jconrel.2013.04.022 ↗
36. 10.1016/j.jconrel.2013.10.03410.1016/j.jconrel.2013.10.034 ↗
37. 10.1007/12_10010.1007/12_100 ↗
38. 10.1021/acsbiomaterials.5b0033510.1021/acsbiomaterials.5b00335 ↗
39. 10.1021/bm401050j10.1021/bm401050j ↗
40. 10.1002/smll.20170127610.1002/smll.201701276 ↗
41. 10.1186/s13287-017-0569-310.1186/s13287-017-0569-3 ↗
42. 10.1038/ncb216410.1038/ncb2164 ↗
43. 10.1161/CIRCRESAHA.112.30062510.1161/CIRCRESAHA.112.300625 ↗
44. 10.1126/science.aaf150210.1126/science.aaf1502 ↗
45. 10.1002/adma.20160323910.1002/adma.201603239 ↗
46. 10.1002/adhm.20160140610.1002/adhm.201601406 ↗
47. 10.2217/nnm.11.1910.2217/nnm.11.19 ↗
48. 10.1080/0036551015109766510.1080/00365510151097665 ↗
49. 10.1161/01.RES.77.4.75010.1161/01.RES.77.4.750 ↗
50. 10.1016/j.ijpharm.2011.10.03410.1016/j.ijpharm.2011.10.034 ↗
51. 10.1016/j.biomaterials.2006.03.03910.1016/j.biomaterials.2006.03.039 ↗
52. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
53. 10.1016/j.ajps.2013.07.00110.1016/j.ajps.2013.07.001 ↗
54. 10.1021/ja803947s10.1021/ja803947s ↗
55. 10.1021/bc049853x10.1021/bc049853x ↗
56. 10.1021/bc100542r10.1021/bc100542r ↗
57. 10.2337/diabetes.52.3.58810.2337/diabetes.52.3.588 ↗
58. 10.1021/jm010493y10.1021/jm010493y ↗
59. 10.1002/adma.20100030710.1002/adma.201000307 ↗
60. 10.1016/j.biomaterials.2014.10.07910.1016/j.biomaterials.2014.10.079 ↗
61. 10.1042/bj184054710.1042/bj1840547 ↗
62. 10.1016/S0003-4975(01)03284-210.1016/S0003-4975(01)03284-2 ↗
63. 10.1161/CIRCRESAHA.109.21610110.1161/CIRCRESAHA.109.216101 ↗
64. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
65. 10.1016/j.jconrel.2014.04.01710.1016/j.jconrel.2014.04.017 ↗
66. 10.1186/1477-3155-11-2610.1186/1477-3155-11-26 ↗
67. 10.1161/01.HYP.25.2.22710.1161/01.HYP.25.2.227 ↗
68. 10.1038/srep2561310.1038/srep25613 ↗
69. 10.1097/MOH.0b013e3282f97d8610.1097/MOH.0b013e3282f97d86 ↗
70. 10.1016/j.jacc.2008.11.01410.1016/j.jacc.2008.11.014 ↗
71. 10.2147/IJN.S13194910.2147/IJN.S131949 ↗
72. 10.2217/nnm.16.2610.2217/nnm.16.26 ↗
73. 10.1007/978-1-4939-6588-5_510.1007/978-1-4939-6588-5_5 ↗
74. 10.4330/wjc.v8.i2.16310.4330/wjc.v8.i2.163 ↗
75. 10.1016/j.addr.2014.08.00610.1016/j.addr.2014.08.006 ↗
76. 10.1161/CIRCRESAHA.112.27114810.1161/CIRCRESAHA.112.271148 ↗
77. 10.1161/CIRCRESAHA.112.26903510.1161/CIRCRESAHA.112.269035 ↗
78. 10.1016/j.stemcr.2013.07.00510.1016/j.stemcr.2013.07.005 ↗
79. 10.1016/j.chembiol.2006.08.00410.1016/j.chembiol.2006.08.004 ↗
80. 10.1073/pnas.090159210610.1073/pnas.0901592106 ↗
81. 10.1002/adma.20140540810.1002/adma.201405408 ↗
82. 10.1016/j.biomaterials.2016.03.04610.1016/j.biomaterials.2016.03.046 ↗
83. 10.1074/jbc.M30271920010.1074/jbc.M302719200 ↗
84. 10.1016/0014-4827(70)90333-210.1016/0014-4827(70)90333-2 ↗
85. 10.1006/jmcc.1996.036310.1006/jmcc.1996.0363 ↗